GeneDx Current Deferred Revenue from 2010 to 2026
| WGS Stock | 90.67 0.77 0.84% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 36 K | Current Value 34.2 K | Quarterly Volatility 829.8 K |
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Interest Income of 3.1 M, Depreciation And Amortization of 28.4 M or Interest Expense of 2.7 M, as well as many indicators such as Price To Sales Ratio of 5.59, Dividend Yield of 0.0 or PTB Ratio of 9.21. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
GeneDx | Current Deferred Revenue | Build AI portfolio with GeneDx Stock |
The evolution of Current Deferred Revenue for GeneDx Holdings Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how GeneDx Holdings compares to historical norms and industry peers.
Latest GeneDx Holdings' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of GeneDx Holdings Corp over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. GeneDx Holdings' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
GeneDx Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,192,718 | |
| Geometric Mean | 531,534 | |
| Coefficient Of Variation | 69.57 | |
| Mean Deviation | 763,895 | |
| Median | 1,783,000 | |
| Standard Deviation | 829,804 | |
| Sample Variance | 688.6B | |
| Range | 1.7M | |
| R-Value | (0.84) | |
| Mean Square Error | 216.7B | |
| R-Squared | 0.71 | |
| Significance | 0.000025 | |
| Slope | (137,976) | |
| Total Sum of Squares | 11T |
GeneDx Current Deferred Revenue History
About GeneDx Holdings Financial Statements
GeneDx Holdings shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although GeneDx Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in GeneDx Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on GeneDx Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 36 K | 34.2 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.